Poster

In vitro genome editing for testing potential gRNAs in CRISPR/Cas9 strategy



C. Díaz-Muñoz, F. Porro, Andrés F. Muro

International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149 - Trieste, Italy.

Keywords: CRISPR/Cas9; Genome Editing;

ABSTRACT

Motivation: CRISPR/Cas9 is a promising strategy that improves the efficacy of homology recombination, opening a wide number of possibilites for genome editing. The use of this technology on the reparation of single nucleotide mutations is being under investigation to recover the phenotype of a number of diseases, as the Crigler-Najjar syndrome.

Methods: The genomic target sequence of the Ugt1a1 mouse gene was cloned into vectors that were designed to assess efficiency in the generation of double strand brakes (DSB) by engineered nucleases. We have designed different sgRNAs targeting this genomic region. The vectors were transfected into Hek293 together with a plasmid expressing the Cas9 nuclease and the sgRNA, generating a DSB in the target sequence. After recombination, the inactive luciferase gene recovers activity, which is proportional to the cutting efficiency of the nuclease. Then, luciferase and T7 assays were used to determine the activity of gRNAs to target the specific genome locus.

Results: Depending on the DNA sequence where is located the gRNA and, specially, the PAM sequences, we have obtained different results on the activity of our gRNAs. However, different factors, as the type of cells transfected or the vectors used, can affect the final activity of the gRNAs and thus, the whole CRISPR/Cas9 activity.

Conclusions: With this project, it has been demonstrated the importance of a good design and optimization of the protocols to choose the most efficient gRNAs for CRISPR/Cas9 machinery, as well as in the vectors used to synthetize all the components needed.

REFERENCES

Jian-Hua Zhang, Poorni Adikaram, Mritunjay PAndey, Allison Genis, and William F. Simonds. (2016) Optimization of genome editing through CRISPR-Cas9 engineering. Bioengineered. Vol. 7, NO3, 166-174, doi: 10.1080/21655979.2016.1189039

Giulia Bortolussi, Lorena Zentilin, Gabriele Baj, Pablo Giraudi, Cristina Bellarosa, Mauro Giacca, Claudio Tiribelli and Andrés F. Muro. (2012) Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer. The FASEB Journal. Vol 26, 1052-1063, doi: 10.1096/fj.11195461

Rajiv Sharma et al. (2015) In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood. Vol. 126, 1777-1784, doi: 10.1182/blood-2014-12-615492.

